

Mayinuer Maitituoheti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1046148/publications.pdf>

Version: 2024-02-01

9
papers

370
citations

1163117
8
h-index

1474206
9
g-index

9
all docs

9
docs citations

9
times ranked

730
citing authors

#	ARTICLE	IF	CITATIONS
1	KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer. <i>Cancer Cell</i> , 2020, 37, 599-617.e7.	16.8	137
2	Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression. <i>Cell Reports</i> , 2017, 19, 875-889.	6.4	78
3	Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma. <i>Cell Reports</i> , 2020, 33, 108293.	6.4	39
4	Atypical plant homeodomain of UBR7 functions as an H2BK120Ub ligase and breast tumor suppressor. <i>Nature Communications</i> , 2019, 10, 1398.	12.8	35
5	Chromatin state dynamics confers specific therapeutic strategies in enhancer subtypes of colorectal cancer. <i>Gut</i> , 2022, 71, 938-949.	12.1	25
6	An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput CHIP-sequencing in Tumor Tissues. <i>Journal of Visualized Experiments</i> , 2018, , .	0.3	24
7	Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy. <i>Cell Reports</i> , 2021, 36, 109410.	6.4	17
8	The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma. <i>Nature Communications</i> , 2022, 13, .	12.8	14
9	KMT2D deficiency confers a therapeutic vulnerability to glycolytic and IGFR inhibitors in melanoma. <i>Molecular and Cellular Oncology</i> , 2021, 8, 1984827.	0.7	1